Skip to content
2000
Volume 4, Issue 4
  • ISSN: 2666-7967
  • E-ISSN: 2666-7975

Abstract

Background: In response to the global outbreak of SARS-CoV-2, researchers have been conducting extensive investigations into potential drug candidates for combating coronavirus infections. One such focus has been on the ethanolic extract of haustorium. While various components of have been explored for their pharmaceutical applications, the potential of the haustorium remains relatively unexplored in this context.Objective: This study aimed to assess the phytocompounds from haustorium using GC MS analysis, evaluate their drug-likeness properties, and perform molecular docking against crucial proteins involved in SARS-CoV-2 infection, namely the Main protease (6LU7), Spike trimer (7AD1), and ACE2 receptor (1R42). The goal was to identify promising compounds with good binding affinity as potential candidates for preventing coronavirus infection.Methods: The ethanolic extract of haustorium underwent GC-MS analysis to identify phytocompounds. Drug-likeness properties of screened compounds were assessed using the Swiss ADME, followed by molecular docking against COVID-19 protein targets using PyRx.Results: The phytocompounds from haustorium namely Phenanthro[1,2-b]furan- 10,11-dione, 6,7,8,9-tetrahydro-1,6,6-trimethyl-, Ethanone, 1-phenyl-2-(4,5-diphenyl-2- imidazolylthio)-, and Thiazolo[3.2-a]benzimidazol-3(2H)-one, 2-(4-acetoxybenzylideno)-, exhibit binding affinities of -7.3, -8.8, and -7.3 for the Main protease, -8, -8.5, and -9.2 for the Spike protein, and -8, -8.1, and -7.9 for the ACE2 receptor, respectively exhibited favourable interactions with COVID-19 protein targets. This suggests their potential as promising drug candidates for preventing coronavirus infection. Despite limited previous exploration, the haustorium emerges as a rich source of such candidates.Conclusion: The study underscores the significance of investigating the haustorium of Borassus flabellifer identified in this study holds promise as a potential breakthrough treatment for COVID- 19-associated disease and the need for further investigations and experimental studies is warranted to validate these findings.

Loading

Article metrics loading...

/content/journals/covid/10.2174/0126667975267554231013112949
2023-12-01
2025-09-08
Loading full text...

Full text loading...

/content/journals/covid/10.2174/0126667975267554231013112949
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test